The Cost of Chronic Myeloid Leukemia Therapy, Financial Toxicity, and the Mark Cuban Effect

Drs Michael J. Mauro and Hagop Kantarjian discuss the cost of chronic myeloid leukemia therapy, long-term safety, adverse events, and the financial toxicity to the patient and the healthcare system.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989022). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Chronic Myelogenous Leukemia (CML) https://emedicine.medscape.com/article/199425-overview

Influence of the 'Mark Cuban Effect' on Cancer Drug Prices in the United States: Focus on CML https://ascopost.com/issues/february-10-2023/influence-of-the-mark-cuban-effect-on-cancer-drug-prices-in-the-united-states-focus-on-cml/

Response and Resistance to BCR-ABL1-targeted Therapies https://pubmed.ncbi.nlm.nih.gov/32289275/

Imatinib (Rx) https://reference.medscape.com/drug/gleevec-imatinib-342239

Tyrosine Kinase Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK563322/

National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER). Cancer Stat Facts: Leukemia — Chronic Myeloid Leukemia (CML) https://seer.cancer.gov/statfacts/html/cmyl.html

Management of Chronic Myeloid Leukemia in 2023 - Common Ground and Common Sense https://pubmed.ncbi.nlm.nih.gov/37088793/

Assessment of Imatinib as First-line Treatment of Chronic Myeloid Leukemia: 10-year Survival Results of the Randomized CML Study IV and Impact of Non-CML Determinants https://pubmed.ncbi.nlm.nih.gov/28804124/

Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management With Clinical Pharmacology https://pubmed.ncbi.nlm.nih.gov/28059038/

Dasatinib (Rx) https://reference.medscape.com/drug/sprycel-dasatinib-342199

Nilotinib (Rx) https://reference.medscape.com/drug/tasigna-nilotinib-342198

Ponatinib (Rx) https://reference.medscape.com/drug/iclusig-ponatinib-999800

Asciminib https://reference.medscape.com/drug/scemblix-asciminib-4000255

Treatment-free Remission: The New Goal in CML Therapy https://pubmed.ncbi.nlm.nih.gov/34618317/

Monitoring Molecular Response in Chronic Myeloid Leukemia https://pubmed.ncbi.nlm.nih.gov/20960522/

Cost Plus Drugs https://costplusdrugs.com/

U.S. Health Care From a Global Perspective, 2022: Accelerating Spending, Worsening Outcomes https://www.commonwealthfund.org/publications/issue-briefs/2023/jan/us-health-care-global-perspective-2022